Developing countries should take a streamlined, regional approach to regulating clinical trials for drugs against neglected tropical diseases (NTDs), in which a single approval would cover multiple countries. Most NTDs have no effective treatments but, thanks to a large investment in recent years from philanthropic foundations, nearly 240 drug and vaccine candidates are now in development, 90 of which are waiting for late stage clinical trials.
The African Union is also about to receive grants from the Bill and Melinda Gates Foundation via the World Bank and the New Partnership for Africa's Development (NEPAD) to carry out joint assessments of clinical trials. Clinical trials represent as much as 70 per cent of the cost, and most of the time, required to develop a drug or vaccine, says the report. Developing all 90 promising candidates that are ready for phase III trials will cause a funding crunch.
You received this message because you are subscribed to the "USA-Africa Dialogue Series" moderated by Toyin Falola, University of Texas at Austin.
For current archives, visit http://groups.google.com/group/USAAfricaDialogue
For previous archives, visit http://www.utexas.edu/conferences/africa/ads/index.html
To post to this group, send an email to USAAfricaDialogue@googlegroups.com
To unsubscribe from this group, send an email to USAAfricaDialogue-
unsubscribe@googlegroups.com
No comments:
Post a Comment